



**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom  
[gov.uk/mhra](http://gov.uk/mhra)

Ms Angela Shone  
UNIVERSITY OF NOTTINGHAM  
EAST ATRIUM, JUBILEE CONFERENCE CENTRE, TRIUMPH ROAD, NOTTINGHAM, NG8 1DH, UNITED  
KINGDOM

22/11/2019

Dear Ms Angela Shone,

**THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031**

Our Reference:	CTA 03057/0070/001-0003
Eudract Number:	2018-001904-12
Product:	DDAVP INJECTION 4MCG/ML
Protocol number:	18040
Substantial Amendment Code Number:	Code Number: SA/03/19 Version: Date: 2019/08/21

**NOTICE OF ACCEPTANCE OF AMENDMENT**

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 30/10/2019.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit  
MHRA**